Pregnant patients with T2IDs using dupilumab did not have an increased rate of adverse events when compared with patients not receiving dupilumab.

Kymera Therapeutics Inc (KYMR) showcases robust financial health and strategic pipeline advancements amid competitive ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...

Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

Saudi Society of Dermatology and Sanofi Sign MoU to Advance Dermatological Care in Saudi Arabia ...

Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.

SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

Pulmonologists alarmed by climate-linked asthma surge, find hope in novel medications: Nandita Vijayasimha, Bengaluru Tuesday, May 6, 2025, 08:00 Hrs [IST] Pulmonologists associat ...

Patients who are immunocompromised still can receive a variety of vaccinations based on their specific needs, Cassandra ...

Shares of Corvus Pharmaceuticals, Inc. (CRVS) traded 30% higher on Friday afternoon after Oppenheimer raised its price target ...